#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Czech-Slovak Pediatrics / 2022 - Supplementum 3

First experience with long-acting growth hormone

Česká verzia

Authors: Lebl Jan 1;  Toni Ledjona 1;  Dankovčíková Adriana 2;  Košťálová Udmila 3;  Magnová Olga 4;  Koloušková Stanislava 1
Authors place of work: Pediatrická klinika, 2. lékařská fakulta Univerzity, Karlovy a FN Motol, Praha 1;  Klinika detí a dorastu, Detská fakultná nemocnica, Košice 2;  Detská klinika, Lekárska fakulta Univerzity, Komenského a Národný ústav, detských chorôb, Bratislava 3;  Pediatrická klinika, FN Brno 4
Published in the journal: Čes-slov Pediat 2022; 77 (Supplementum 3): 36-40.
Category:
doi: https://doi.org/10.55095/CSPediatrie2022/057

Summary

Therapeutic use of growth hormone spans back over 65 years. The drug molecule remained unchanged, despite a switch in production technology. It is being administered in form of subcutaneous daily injections for multiple years in most patients, which may represent a significant burden for the child and his/her family. Three modified molecules of long-acting growth hormone (LAGH) with once weekly administration have been developed and are approaching clinical use. Their growth effect is equivalent to daily growth hormone injections. Lonapegsomatropin is a pegylated pro-molecule temporarily conjugated with a carrier, allowing regular release of native growth hormone. Somapacitan has one amino acid substitute in growth hormone molecule, serving as an anchor for a fatty acid with bound plasmatic albumin. Its substantially prolonged half-life allows gradual conversion into active molecule. Somatrogon is growth hormone fused with natural human peptide (CTP technology) which slows down its renal and hepatic clearance and prolongs sevenfold its half-life. We participated at an international multicentre clinical study to test treatment burden of somatrogon administration in comparison to daily growth hormone, using standardised questionnaires. The cohort of 87 children and their families reported significantly declined treatment burden during somatrogon therapy to one third in comparison to daily injections. LAGH will soon become a novel treatment option for children with some forms of short stature.

Keywords:

Growth hormone – long-acting growth hormone – lonapegsomatropin – somapacitan – somatrogon

Zdroje
  1. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958; 18: 901–903.
  2. Reh CS, Geffner ME. Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review. Clin Pharmacol 2010; 2: 111–122.
  3. Ranke MB, Wit JM. Growth hormone – past, present and future. Nat Rev Endocrinol 2018; 14: 285–300.
  4. Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol 2010; 6: 515–525.
  5. Waters MJ. The growth hormone receptor. Growth Horm IGF Res 2016; 28: 6–10.
  6. Albertsson-Wikland K, Westphal O, et al. Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand 1986; 75: 89–97.
  7. Ranke MB. Clinical experience with authentic recombinant human growth hormone. Acta Paediatr Scand Suppl 1986; 325: 90–92.
  8. Kastrup KW, Christiansen JS, Andersen JK, et al. Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children. Acta Endocrinol (Copenh) 1983; 104: 148–152.
  9. Cutfield WS, Derraik JGB, Gunn AJ, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PloS One 2011; 6: e16223-e16223.
  10. Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008; 93: 147–148.
  11. Lippe B, Frasier SD, Kaplan SA. Use of growth hormone-gel. Arch Dis Child 1979; 54: 609–613.
  12. Johnson OL, Cleland JL, Lee HJ, et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med 1996; 2: 795–799.
  13. Cai Y, Xu M, Yuan M, et al. Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. Int J Nanomedicine 2014; 9: 3527–3538.
  14. Miller BS, Velazquez E, Yuen KCJ, et al. Long-acting growth hormone preparations – current status and future considerations. J Clin Endocrinol Metab 2020; 105: e2121–e2133.
  15. Luo X, Hou L, Liang L, et al. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol 2017; 177: 195–205.
  16. Thornton PS, Maniatis AK, Aghajanova E, et al. Weekly lonapegsomatropin in treatment naïve children with growth hormone deficiency: the phase 3 height trial. J Clin Endocrinol Metab 2021; 106: 3184–3195.
  17. Thygesen P, Andersen HS, Behrens C, et al. Nonclinical pharmaco-kinetic and pharmacodynamic characterisation of somapacitan: A reversible non- -covalent albumin-binding growth hormone. Growth Horm IGF Res 2017; 35: 8–16.
  18. Fisher DM, Rosenfeld RG, Jaron-Mendelson M, et al. Pharmacokinetic and pharmacodynamic modeling of MOD-4023, a long-acting human growth hormone, in growth hormone deficiency children. Horm Res Paediatr 2017; 87: 324–332.
  19. Zelinska N, Iotova V, Skorodok J, et al. Long-acting C-terminal peptide- -modified hGH (MOD-4023): Results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab 2017; 102: 1578–1587.
  20. Sävendahl L, Battelino T, Brod M, et al. Once weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial. J Clin Endocrinol Metab 2020; 105: e1847–e1861.
  21. Allen DB, Merchant N, Miller BS, et al. Evolution and future of growth plate therapeutics. Horm Res Paediatr 2021; 94: 319–332.
  22. Maniatis AK, Carakushansky M, Galcheva S, et al. Treatment burden of weekly somatrogon vs daily genotropin in children with growth hormone deficiency: a randomized study. J Endocr Soc 2022; in press.
Štítky
Neonatology Paediatrics General practitioner for children and adolescents
Článek Vážení kolegové, přátelé, pediatři z primární péče, z regionálních nemocnic i z klinik,
Článek Minipuberty – an important and still neglected period of sexual development
Článek Current perspectives on the aetiology of tall stature in children and adolescents (1): Syndromes associated with tall stature
Článek Current perspectives on the aetiology of tall stature in children and adolescents (2): Non-syndromic tall stature
Článek Endocrine causes of obesity in childhood and adolescence
Článek Children and adolescents with gender incongruence: current approaches and situation in the Czech Republic
Článek Mystický Hagibor a jeho místo v historii české pediatrie
Článok vyšiel v časopise

Czech-Slovak Pediatrics

Číslo Supplementum 3
2022 Číslo Supplementum 3
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#